<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089970</url>
  </required_header>
  <id_info>
    <org_study_id>637013</org_study_id>
    <secondary_id>1K23HL127185-01A1</secondary_id>
    <nct_id>NCT03089970</nct_id>
  </id_info>
  <brief_title>Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients</brief_title>
  <official_title>Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory virus infections cause a majority of asthma exacerbations in the fall to spring
      months. Current diagnostic platforms for respiratory viruses have limitations including cost,
      availability, and invasiveness. The use of noninvasive breath collection to analyze breath
      metabolites may be used to differentiate virus-infected asthmatics from other causes of acute
      asthma exacerbations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Breath metabolite differences between groups</measure>
    <time_frame>36 months</time_frame>
    <description>Metabolites from breath will be identified and quantified using gas chromatography-mass spectrometry; these will be compared between groups. Specific breath metabolites include isoprostane, linear and branched alkanes (C6-C9), alcohols, and thiol-containing moieties. However, we will also measure metabolites in an un-targeted manner.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Upper Respiratory Tract Infections, Asthma, Exhaled Breath</condition>
  <arm_group>
    <arm_group_label>Healthy asthma</arm_group_label>
    <description>Asthmatic patients not with an exacerbation, i.e., stable asthmatics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhinovirus-infected asthmatics</arm_group_label>
    <description>Asthmatics with an exacerbation and associated rhinovirus infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza A-infected asthmatics</arm_group_label>
    <description>Asthmatics with an exacerbation and associated influenza A infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Exhaled breath condensate collection</intervention_name>
    <description>Breath from humans is cooled, condensed, and collected</description>
    <arm_group_label>Healthy asthma</arm_group_label>
    <arm_group_label>Rhinovirus-infected asthmatics</arm_group_label>
    <arm_group_label>Influenza A-infected asthmatics</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Exhaled breath condensate
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with asthma with or without an acute exacerbation will be recruited
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asthma, Age ≥12, Symptoms/signs of an early asthma exacerbation, Ability to provide
             exhaled breath condensate (EBC) x15 min, Body mass index (BMI) ≥18

        Exclusion Criteria:

          -  Chronic lung diseases other than asthma (e.g., chronic obstructive pulmonary disease
             [COPD], lung cancer, fibrotic lung disease, etc.), Smoking in the past 7 days, Eating
             or non-clear liquids &lt;4 hrs prior to EBC collection, Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schivo, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Schivo, MD, MAS</last_name>
    <phone>(916) 734-3564</phone>
    <email>mschivo@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Davis Medical Ceneter</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schivo, MS, MAD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

